|
Patient-reported outcomes for the phase 3 TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. |
| |
|
Employment - HCA Healthcare |
Leadership - HCA Healthcare |
Stock and Other Ownership Interests - HCA Healthcare |
Research Funding - Abbvie (Inst); Agios (Inst); Archer (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BioAtla (Inst); BioMed Valley Discoveries (Inst); BioTheryX (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CALGB (Inst); CicloMed (Inst); Coordination Pharmaceuticals (Inst); CytomX Therapeutics (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Foundation Medicine (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gossamer Bio (Inst); Harpoon therapeutics (Inst); Hengrui Therapeutics (Inst); Incyte (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Kymab (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Moderna Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst); Revolution Medicines (Inst); Roche/Genentech (Inst); Ryvu Therapeutics (Inst); Seagen (Inst); Takeda/Millennium (Inst); Tesaro (Inst); TG Therapeutics (Inst); Verastem (Inst); Vertex (Inst); XBiotech (Inst); Zymeworks (Inst) |
(OPTIONAL) Uncompensated Relationships - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); GRAIL (Inst); Incyte (Inst); Novartis (Inst); TG Therapeutics (Inst); Vincerx Pharma (Inst) |
| |
|
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Incyte; Lilly; Nihon Servier; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha |
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Dainippon Sumitomo Pharma; Eisai; FUJIFILM Toyama Chemistry; Nihon Servier; Taiho Pharmaceutical |
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Eisai (Inst); MSD (Inst); Novartis (Inst); Novartis (Inst); Syneos Health/Immunocore (Inst); Taiho Pharmaceutical (Inst) |
| |
|
Honoraria - Advanced Accelerator Applications/Imaging Equipment Ltd; Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Daichi-Sankyo; Incyte; Ipsen; Janssen; Lilly; MSD; Pierre Fabre; Roche; Sanofi; Sirtex Medical; TERUMO; TERUMO |
Consulting or Advisory Role - Amgen; AstraZeneca; Baxalta; Bayer; BTG; Daichi-Sankyo; Eisai; IPSEN; Lilly; Novartis; Pierre Fabre; Roche; Sirtex Medical; Terumo |
Research Funding - Novartis |
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; Roche |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - Daiichi Sankyo; Mylan; Taiho Pharmaceutical; Yakult Pharmaceutical |
Research Funding - AstraZeneca Canada; Daiichi Sankyo; Taiho Pharmaceutical |
| |
Valeriy Vladimirovich Breder |
Honoraria - AstraZeneca; Bristol-Myers Squibb; Eisai; MSD Oncology; Roche; Takeda |
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; MSD Oncology; Roche; Takeda |
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Ipsen; Roche; Takeda |
| |
|
Honoraria - AstraZeneca Canada; Bayer; Eisai; Ipsen; MSD; Roche |
Consulting or Advisory Role - AstraZeneca; Bayer; Eisai; Ipsen; MSD; Roche |
| |
|
No Relationships to Disclose |
| |
|
|
Stock and Other Ownership Interests - AstraZeneca |
| |
|
|
Stock and Other Ownership Interests - AstraZeneca |
| |
|
|
Consulting or Advisory Role - AstraZeneca |
| |
|
|
Stock and Other Ownership Interests - AstraZeneca |
| |
|
|
Stock and Other Ownership Interests - AstraZeneca |
| |
|
|
Travel, Accommodations, Expenses - AstraZeneca |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - ASLAN Pharmaceuticals; AstraZeneca; Basilea; Bayer; BeiGene; Celgene; Genentech/Roche; Halozyme; Merck Serono; Novartis; Taiho Pharmaceutical; Turning Point Therapeutics; Zymeworks |
Research Funding - Array BioPharma; AstraZeneca; BeiGene; Handok; Lilly; MSD; Novartis; SERVIER |